Prospective Multicenter Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

Brief description of study

The purpose of this study is to demonstrate the effectiveness of Riociguat as replacement of PDE-5i therapy (Sildenafil or Tadalafil) in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i: Sildenafil or Tadalafil) with or without endothelin receptor antagonist (a drug that blocks endothelin receptors), but the treatment has not reached its goal. Riociguat (Brand name: Adempas) is approved by Health Authorities including the FDA (Food and Drug Administration) for the treatment of Pulmonary arterial hypertension.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.